Ocaliva is a drug used to treat primary biliary cholangitis (PBC), a chronic liver disorder, and polycystic kidney disease (PKD), a genetic disorder that affects the kidneys. It is a small molecule inhibitor of the enzyme farnesoid X receptor (FXR), which is involved in the regulation of bile acid metabolism. Ocaliva is the only approved FXR agonist for the treatment of PBC and PKD. It is available in both oral and intravenous formulations. Ocaliva is marketed by Intercept Pharmaceuticals, a biopharmaceutical company based in the United States. Other companies in the market include Gilead Sciences, Merck, and Novartis. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
